ClinicalTrials.gg
RecruitingNCT07864207MYCrocyticUpdated Oct 7, 2026

Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

A Phase 1/2 interventional study of IDP-121 in Small Cell Lung Cancer ( SCLC ), sponsored by IDP Discovery Pharma S.L.. Recruiting at 10 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by IDP Discovery Pharma S.L. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Small Cell Lung Carcinoma with a site in Spain — 38 open to participants now, 65 under way, 23 of them phase 3. Small Cell Lung Carcinoma · Spain.

Planned enrollment
105th of 135
60 · median 184
Started
2026
with 14 others
Phase 1/2
26 of 141
13 open now
Primary completion
2028-07
later than 36 of 64 live
Registered
141st of 141
by date

Among the 141 studies in Small Cell Lung Carcinoma with a site in Spain, this one is the 105th largest by planned enrollment of the 135 interventional ones that give a count, is one of 15 that started in 2026, is one of 26 in phase 1/2, reaches primary completion later than 36 of the 64 other live ones, and was the 141st registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

38 of the 141 studies in Small Cell Lung Carcinoma with a site in Spain are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Small Cell Lung Carcinoma with a site in Spain, or all of them as a file.
02

Study summary

Phase 1/2 clinical trial is to evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of IDP-121 combined with chemotherapy in patients with advanced unresectable/metastatic SCLC that have progressed after 1st line platinum- based chemotherapy, considering the role of MYC amplification in the development of platinum resistance.

03

Conditions studied

  • Small Cell Lung Cancer ( SCLC )
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Performance status () ≤ 2
  3. ≥2 months
  4. Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.
  5. Patient has given voluntary written before performance of any study- related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
  6. Patients diagnosed with advanced/extensive stage SCLC that have platinum-sensitive relapse after treatment defined as a Progression Free Interval (PFI) of ≥ 3 months (platinum-based chemotherapy plus IDP-121 arm) and patients with a PFI \< 3 months (topotecan plus IDP-121 arm).
  7. Adequate haematological or biochemical parameters as specified below

    a. b. > 8.0 g/dl (without transfusion support within 7 days) count > 100 x109/L (without transfusion support within 7 days). c. (ANC) > 1.5 x109/L (without G-CSF support within 7 days) d. (AST): \<2.5 x the upper limit range. e. Alanine transaminase (ALT): \< 2.5 x the upper limit range. f. Total : \< 2 x the upper limit range. g. Calculated or measured : ≥ 60 mL/min (calculated from the Cockcroft-Gault formula).

  8. > 50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower, determined by echocardiogram.

Exclusion criteria

Exclusion Criteria:

  1. Persistent or grade 3 or 4 non-haematological toxicity related to previous treatments. The presence of alopecia and NCI-CTC grade \<2 symptomatic peripheral neuropathy is allowed.
  2. Active and/or carcinomatous meningitis. Participants with previously treated brain metastases (e.g., whole brain radiation treatment [WBRT], stereotactic radiosurgery, or equivalent) may participate only if they satisfy the following:
  3. 4. 5. 6. 7. 8. 9. • Completed treatment at least 14 days prior to the first dose of study intervention.

    • Are clinically stable, without requirement of treatment > 10 mg or prednisone or equivalent for at least 7 days prior to first dose of study intervention. Pregnant or lactating women; men and women of * (as defined in the Appendix 2) who are not using effective methods (combined hormonal contraception associated with inhibition of ovulation; progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence).

      *A woman is considered of (WOCBP), i.e. fertile, following menarche and until becoming unless permanently sterile. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.

    History of any other neoplastic disease in the last five years (except basal cell carcinoma, skin epithelioma or carcinoma in situ of any site) History of clinically significant hypotension. History of clinically significant allergic or hyper-sensitivity reactions. History or known clinically significant vascular disease or known high risk of vascular disease (as assessed by the treating physician) including (but not limited to): - Thromboembolism - Peripheral arterial disease

    - Vasculitis

    Other relevant diseases or adverse clinical conditions:

    - Congestive heart failure or angina pectoris, myocardial infarction within 12 months before inclusion in the study.

    • Uncontrolled arterial hypertension or cardiac arrhythmias (i.e., requiring a change in medication within the last 3 months or hospital admission within the past 6 months).
    • History of significant neurological or psychiatric disorders Clinically significant or active infection.

10. Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis) 11. The patient is known to be (HIV) positive, unless the patient is on antiviral therapy with HIV RNA levels \<50 copies/mL; surface antigen-positive or active infection, unless treated with undetectable hepatitis B DNA or hepatitis C RNA levels; or active CMV infection (IgM positive). 12. Concomitant anti-tumour therapy within 14 days prior to Day 1 of Cycle 1. 13. Prior transplantation in the last 3 months or currently active with treatment 14. Limitation of the patient's ability to comply with the treatment or follow-up protocol.

15. If a COVID-19 vaccine is administered, it should be done >72 hours prior to study treatment initiation or after the completion of the dose-limiting toxicity (DLT) period (if patient is participating in the dose-escalation phase").

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    IDP-121 with Topotecan

    IDP-121 in combination with topotecan in patients with relapsed SCLC with PFI \< 3 months

    Drug: IDP-121

  • Experimental
    IDP-121 with platinum-based chemotherapy

    IDP 121 in combination with platinum-based chemotherapy in patients with relapsed SCLC and PFI ≥ 3 months

    Drug: IDP-121

Interventions

06

What researchers measure

Primary outcomes

  1. MTD and RP2D

    To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 combined with chemotherapy (topotecan day 1 to 5 every 3 weeks; carboplatin day 1 plus etoposide days 1, 2 and 3 every 3 weeks) in patients with SCLC.

    Time frame: 1 year

07

Study locations

6 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 24 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 7, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Jul 30, 2028
CompletionEst.
Jul 30, 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864207
Lead sponsor
IDP Discovery Pharma S.L.
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Jul 28, 2026
Primary completion
Jul 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

David Molina, Doctor
Contact
d.molina@idp-pharma.com
+34 669 616 086

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IDP-121

Start the discussion